I am a
Home I AM A Search Login

Papers of the Week

Papers: 7 May 2022 - 13 May 2022

Pharmacology/Drug Development

2022 May 10

Pain Ther

Efficacy, General Safety, and Joint Safety of Tanezumab in Japanese Patients with Osteoarthritis: Subgroup Analyses from Two Randomized, Phase 3 Studies.


Miki K, Ohta M, Abe M, Yoshimatsu H, Fujii K, Ebata N, West CR, Brown MT, Pixton G, Isogawa N
Pain Ther. 2022 May 10.
PMID: 35538185.


Tanezumab is a monoclonal antibody against nerve growth factor that is under investigation for the treatment of osteoarthritis (OA) pain. We conducted subgroup analyses of two randomized phase 3 studies to summarize efficacy, general safety, and adjudicated joint safety of tanezumab in Japanese patients with moderate-to-severe OA.